ArticleJHEP reports : innovation in hepatology2025

Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.

Sarah K Browne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.